PL EN


Preferences help
enabled [disable] Abstract
Number of results
2009 | 7 | 3 | 199-205
Article title

Ocena stężenia bFGF w surowicy krwi kobiet z guzami złośliwymi i niezłośliwymi jajnika

Content
Title variants
EN
Analysis of serum bFGF concentration in women with malignant and benign ovarian tumors
Languages of publication
EN PL
Abstracts
EN
Aim of paper: The purpose of this paper was to assess serum bFGF level on women with malignant and benign ovarian cancer. Material and methods: The study encompassed 62 patients treated at the Department of Surgical Gynaecology of the Medical University in Poznań since 2006 thru 2009. The patients were subdivided into two groups: those harboring ovarian cancer (group 1; n=17) and those affected with a benign tumor (group 2; n=45). Serum bFGF level was assessed in both groups in relation to several features of the disease. Results: Median serum bFGF level in group 1 was 40.10 pg/ml (95% CI: 29.17-113.89), while in group 2 – 20.60 pg/ml (95% CI: 16.33-36.59). The difference was close to statistical significance (p=0.068). Prognostic value of bFGF in ovarian cancer in terms of sensitivity and specificity was 47% and 93%, respectively. Its positive predictive value (PPV) was 73%, negative predictive value (NPV) – 82%, and AU-ROC (area under curve) – 0.647. Analysis of AU-ROC for bFGF and CA-125 revealed superior predictive value of the latter in ovarian cancer (p=0.011). Median serum bFGF level in women with ovarian cancer at FIGO stage III and IV was 99.60 pg/ml (95% CI: 37.59-185.04) and was significantly higher than at FIGO stage I and II (16.29 pg/ml; 95% CI: 4.57-37.78; p=0,025). In clear-cell- and non-differentiated cancers, higher serum bFGF level was noticed (p=0.0037). No correlations have been noticed between bFGF and histological malignancy grade (p=0.56) or tumor size (group 1: p=0.56; group 2: p=0.87). Conclusions: In women affected with ovarian cancer, serum bFGF level is higher than in those harboring benign tumors and the difference is close to statistical significance. In women with ovarian cancer, serum bFGF level is significantly higher in those at more advanced clinical stage of the disease. bFGF may be a valuable adjunct in preoperative diagnostic work-up of ovarian tumors.
PL
Cel: Celem pracy była ocena surowiczego stężenia bFGF u kobiet ze złośliwym i niezłośliwym guzem jajnika. Materiał i metody: Badaniami objęto 62 pacjentki leczone w Klinice Ginekologii Operacyjnej UM w Poznaniu w latach 2006-2009. Pacjentki podzielono na dwie grupy: chore z rakiem jajnika (grupa 1.; n=17) i kobiety z guzem niezłośliwym (grupa 2.; n=45). Stężenie bFGF analizowano w poszczególnych grupach w zależności od różnych cech choroby. Wyniki: Mediana stężenia bFGF w grupie 1. wynosiła 40,10 pg/ml (95% CI: 29,17-113,89), natomiast w grupie 2. – 20,60 pg/ml (95% CI: 16,33-36,59). Różnica ta była bliska istotności statystycznej (p=0,068). W prognozowaniu raka jajnika bFGF uzyskał czułość równą 47%, swoistość – 93%, PPV – 73%, NPV – 82% przy polu pod krzywą ROC (AU-ROC) równym 0,647. Analiza AU-ROC dla bFGF i CA-125 wykazała wyższość CA-125 w predykcji raka jajnika (p=0,011). Mediana stężeń bFGF u kobiet z rakiem jajnika w III i IV stopniu według FIGO wynosiła 99,60 pg/ml (95% CI: 37,59-185,04) i była istotnie statystycznie wyższa niż w I i II stopniu FIGO (16,29 pg/ml, 95% CI: 4,57-37,78; p=0,025). W rakach jasnokomórkowych i niezróżnicowanych występowały wyższe stężenia bFGF (p=0,0037). Nie zaobserwowano korelacji między bFGF a stopniem złośliwości histologicznej (p=0,56) ani wielkością guza (grupa 1.: p=0,56; grupa 2.: p=0,87). Wnioski: U kobiet z rakiem jajnika stężenia bFGF są wyższe niż u kobiet z guzami niezłośliwymi, a różnice te są bliskie istotności statystycznej. U kobiet z rakiem jajnika stężenie bFGF jest istotnie wyższe w zaawansowanych stadiach choroby. bFGF może być cennym uzupełnieniem diagnostyki przedoperacyjnej guzów jajnika.
Discipline
Year
Volume
7
Issue
3
Pages
199-205
Physical description
References
  • 1. Wojciechowska U., Didkowska J., Zatoński W.: Nowotwory złośliwe w Polsce w 2006 roku. Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie, Warszawa 2008. Adres: http://www.onkologia.org.pl/doc/Biuletyn2006.pdf.
  • 2. National Cancer Institute. Adres: http://seer.cancer.gov/csr/1975 2006/ browse csr.php?section = 21&page=sect_21_table.07.html.
  • 3. Javerzat S., Auguste P., Bikfalvi A.: The role of fibroblast growth factors in vascular development. Trends Mol. Med. 2002; 8: 483-489.
  • 4. Bugler B., Amalric F., Prats H.: Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor. Mol. Cell. Biol. 1991; 11: 573-577.
  • 5. Jaye M., Schlessinger J., Dionne C.A.: Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim. Biophys. Acta 1992; 1135: 185-199.
  • 6. Presta M., Dell’Era P., Mitola S. i wsp.: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005; 16: 159-178.
  • 7. Bastaki M., Nelli E.E., Dell’Era P. i wsp.: Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 454-464.
  • 8. Nakamura T., Mochizuki Y., Kanetake H., Kanda S.: Signals via FGF receptor 2 regulate migration of endothelial cells. Biochem. Biophys. Res. Commun. 2001; 289: 801-806.
  • 9. Kanda S., Landgren E., Ljungström M., Claesson-Welsh L.: Fibroblast growth factor receptor 1-induced differentiation of endothelial cell line established from tsA58 large T transgenic mice. Cell Growth Differ. 1996; 7: 383-395.
  • 10. Stokes C.L., Rupnick M.A., Williams S.K., Lauffenburger D.A.: Chemotaxis of human microvessel endothelial cells in response to acidic fibroblast growth factor. Lab. Invest. 1990; 63: 657-668.
  • 11. Montesano R., Orci L., Vassalli P.: In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J. Cell Biol. 1983; 97: 1648-1652.
  • 12. Hojilla C.V., Mohammed F.F., Khokha R.: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br. J. Cancer 2003; 89: 1817-1821.
  • 13. Taraboletti G., D’Ascenzo S., Borsotti P. i wsp.: Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am. J. Pathol. 2002; 160: 673-680.
  • 14. Roghani M., Mohammadi M., Schlessinger J., Moscatelli D.: Induction of urokinase-type plasminogen activator by fibroblast growth factor (FGF)-2 is dependent on expression of FGF receptors and does not require activation of phospholipase Cγ1. J. Biol. Chem. 1996; 271: 31154-31159.
  • 15. Fulgham D.L., Widhalm S.R., Martin S., Coffin J.D.: FGF-2 dependent angiogenesis is a latent phenotype in basic fibroblast growth factor transgenic mice. Endothelium 1999; 6: 185-195.
  • 16. Di Blasio A.M., Cremonesi L., Viganó P. i wsp.: Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Am. J. Obstet. Gynecol. 1993; 169: 1517-1523.
  • 17. Crickard K., Gross J.L., Crickard U. i wsp.: Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol. Oncol. 1994; 55: 277-284.
  • 18. Le Page C., Ouellet V., Madore J. i wsp.: From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA-125 as serum-based markers in epithelial ovarian cancer. Int. J. Cancer 2006; 118: 1750-1758.
  • 19. Zhang Y., Guo K.J., Shang H. i wsp.: Expression of aFGF, bFGF, and FGFR1 in ovarian epithelial neoplasm. Chin. Med. J. (Engl.) 2004; 117: 601-603.
  • 20. Obermair A., Speiser P., Reisenberger K. i wsp.: Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett. 1998; 130: 69-76.
  • 21. Yiangou C., Gomm J.J., Coope R.C. i wsp.: Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br. J. Cancer 1997; 75: 28-33.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-11f50a57-9049-4be5-bde3-0b63970a4382
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.